Priority 9 from the Mitochondrial Disease PSP
UNCERTAINTY: Why are people with the same genetic mutation affected so differently in mitochondrial disease? (JLA PSP Priority 9) | |
---|---|
Overall ranking | 9 |
JLA question ID | 0095/9 |
Explanatory note | Not available |
Evidence |
https://pubmed.ncbi.nlm.nih.gov/29880721%20https://pubmed.ncbi.nlm.nih.gov/29560378/ https://pubmed.ncbi.nlm.nih.gov/31253706/ |
Health Research Classification System category | Metabolic and Endocrine |
Extra information provided by this PSP | |
---|---|
Original uncertainty examples | How can family members with the same condition present at different ages with different symptoms? ~ Why do some members of a family get MELAS and others don’t. I carry 20%, my son passed away at [age] from it but my sister and my daughter don’t appear to have any down to 1% that can be tested. ~ Why do similar mutations in mtDNA give rise to such a diversity of phenotypes? ~ What is the importance of heteroplasmy in the brain with respect to CNS phenotypes? Is there regional heteroplasmy within CNS tissue? ~ I would like more research into the effects on carriers of the disease. ~ How does heteroplasmy vary between tissues and cells and what are the mechanisms involved in these changes over time? ~ Why does the heteroplasmy in some gene mutations end up being split between either high or low levels whilst middle levels are a lot more rare? ~ Why one mutation can result in different symptoms in different individuals. ~ Genetic and epigenetic profiling. ~ Role of nuclear modifying genes on mitochondrial DNA |
Submitted by | 6 x Healthcare professionals, 3 x Carers, 1 x Patients |
PSP information | |
---|---|
PSP unique ID | 0095 |
PSP name | Mitochondrial Disease |
Total number of uncertainties identified by this PSP. | 42 (To see a full list of all uncertainties identified, please see the detailed spreadsheet held on the JLA website) |
Date of priority setting workshop | 19 January 2020 |